PharmacoEconomics

, Volume 20, Issue 9, pp 593–602

Cost Effectiveness of Tinzaparin Sodium Versus Unfractionated Heparin in the Treatment of Proximal Deep Vein Thrombosis

  • J. Jaime Caro
  • Denis Getsios
  • Ingrid Caro
  • Judith A. O’Brien
Original Research Article

DOI: 10.2165/00019053-200220090-00003

Cite this article as:
Caro, J.J., Getsios, D., Caro, I. et al. Pharmacoeconomics (2002) 20: 593. doi:10.2165/00019053-200220090-00003

Abstract

Objective: To evaluate economic and health implications of tinzaparin sodium, a once a day low-molecular-weight heparin (LMWH), versus unfractionated heparin (UFH) in the treatment of acute deep vein thrombosis (DVT) from a US healthcare payer perspective.

Study Design: An economic model, composed of two submodules, was created: A short-term module based on clinical trial data covering the first 3 months and a long-term module that projects trial results based on published data for up to 50 years.

Methods: Clinical trial results were combined with data from long-term follow-up studies of DVT in a model that estimates the health and economic consequences of treatment. Both short- and long-term costs with tinzaparin sodium were compared with UFH, as were health outcomes and quality-adjusted life-years (QALYs).

Results: Patients treated with tinzaparin sodium are estimated to live a mean of 0.9 years longer on average (0.6 discounted), resulting in an increase of 0.8 QALYs (0.5 discounted). At the same time, lifetime savings are $US621 per patient (1999 values), even when all patients receiving tinzapirin sodium are treated as inpatients. Early discharge of patients receiving tinzaparin sodium, or outpatient treatment, would save between $US3000 and $US5000 per patient.

Conclusion: Tinzaparin sodium leads to better health outcomes and substantial economic savings compared with UFH treatment when all management costs are considered.

Copyright information

© Adis International Limited 2002

Authors and Affiliations

  • J. Jaime Caro
    • 1
    • 2
  • Denis Getsios
    • 3
  • Ingrid Caro
    • 3
  • Judith A. O’Brien
    • 1
  1. 1.Caro Research InstituteConcordUSA
  2. 2.Division of General Internal Medicine, Royal Victoria HospitalMcGill UniversityMontréalCanada
  3. 3.Caro Research InstituteMontréalCanada

Personalised recommendations